Search for Current Clinical Trials

Study Name Description Trial Category Trial SubCategory
COG: ARST1321 Pazopanib Neoadjuvant triao in Non-Rhabdomyosarcoma soft tissue sarcomas(PAZNTIS): A phase II/III randomized trial preoperative chemoradiation or preop radiation plus or minus Pazopanib Childhood Cancers Sarcoma
COG:ACNS1123 Phase 2 trial of response based radiation therapy for patients with localized central nervous system Germ Cel Tumors Childhood Cancers Tumor
Crest 2 Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial IDE G130221 Heart & Vascular Cardiac Disease
E4512 A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib vs. Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK+) Fusion Protein (ALCHEMIST)(Sub-Study of A151216) Cancer Lung
EA2165 Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer Cancer Gastrointestinal
EA3132 Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing Cancer Head and Neck
EA3161 A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA Cancer Head and Neck
EA5163: INSIGNA: A Randomized Phase III Study of First-line Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post-progression in Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) with Immuno-biomarker SIGNature-driven Analysis Cancer Lung
EA5181 Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC Cancer Lung
GOG-0263 Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy Cancer Gynecologic
Improving Continuous Positive Airway Improving Continuous Positive Airway Pressure Adherence in Patients with Obstructive Sleep Apnea: Impact of Patient and Family Engagement (Improving CPAP Adherence Pulmonary Respiratory
LUNGMAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) Cancer Lung
Merck Keynote MK3475-671 A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable IIB or IIIA Non-small Cell Lung Cancer Cancer Lung
Microbiome: Correlation between Gut Microbiome and Response to Immunotherapy in Cancer Patients. Correlation between Gut Microbiome and Response to Immunotherapy in Cancer Patients. Sparrow and MSU feasibility study to establish the relationship between the success/failure of checkpoint inhibitor therapy and gut biome of cancer patients. Adults prior to starting immunotherapy or healthy adult volunteers. Cancer All tymor types
Node 303 multi-center, open label study to evaluate the safety of etripamil nasal spray in patients with Paroxysmal Supraventricular Tachycardia (PSVT). Heart & Vascular Cardiac Arrhythmia
NRG-BR004 A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer Cancer Metastatic Breast
NRG-GI004 Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy With or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer Cancer Gastrointestinal
NRG-GI005 Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) Cancer Gastrointestinal
NRG-GY018 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Cancer Endometrial
NRG-GY019 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Cancer Ovarian
NRG-HN001 Randomized Phase II AND Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) Cancer Nasopharynx Carcinoma
NRG-HN004 Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin Cancer Head and Neck
NRG-HN005 A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer Cancer Head and Neck
NRG-LU002 Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung – Cancer Cancer Lung
NRG-LU003 A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Master Protocol Cancer Lung
NRG-LU005: Limited Stage Small Cell Lung Cancer A Phase II/III Randomized Study of Chemoradiation VS Chemoradiation Plus Atezolizumab Cancer Lung
NRG-LU007 RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial Cancer Lung
NSABP FB-12: An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1) Cancer Breast
ON-TRK PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib Cancer Genomic
PFO Occulder (PAS) Amplatzer PFO Occluder Post Approval Study (No. SJM-CIP-10187 Ver. A) Heart & Vascular Structural Heart Disease